Inveltys Suspension
Product Images NDC 0065-9307

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Inveltys (NDC 0065-9307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sample-carton (300074556)

Carton label for Inveltys (loteprednol etabonate ophthalmic suspension) 10 mg/mL (1%) by Alcon Laboratories, Inc. The label indicates a sterile 2.8 mL suspension for topical ocular use. It includes dosage instructions, storage requirements, and a tamper-evident seal warning.*

FDA Label Image

28ml-carton (300074557)

The image shows the carton label for Inveltys ophthalmic suspension, loteprednol etabonate 10 mg/mL (1%). It is a 2.8 mL sterile suspension for topical eye application, labeled by Alcon Laboratories, Inc. The label includes storage instructions, active and inactive ingredients, preservative information, barcode, and QR codes.*

FDA Label Image

2.8ml-label (300074563)

Label for Inveltys (loteprednol etabonate ophthalmic suspension) 1% in a 2.8 mL sterile ophthalmic suspension vial. The label includes the NDC 0065-9307-04, manufacturer Alcon Laboratories, Inc., and indicates the product is prescription only. The label also shows an area for lot and expiration information.*

FDA Label Image

Sample-label (300074565)

Inveltys (loteprednol etabonate) ophthalmic suspension 1%, 2.8 mL bottle label. The label indicates the product is sterile, prescription only, and is manufactured by Alcon Laboratories, Inc., Fort Worth, Texas. The label includes the NDC 0065-9307 and a sample designation.*

FDA Label Image

Figure 1 (Figure1)

A bar graph displaying the percent of patients with complete resolution of anterior chamber cells (cell count = 0) comparing Inveltys BID (n=386) and Vehicle (n=385) on Day 8 and Day 15. Inveltys shows higher percentages at both time points, with Day 8 around 24% versus 13%, and Day 15 around 50% versus 27%, indicating a treatment effect.*

FDA Label Image

Figure 2 (Figure2)

A bar graph comparing the percent of patients with complete resolution of pain (Grade 0) over Days 4, 8, and 15 between Inveltys BID (n=386) and Vehicle (n=385). The Inveltys groups show higher percentages of pain resolution at all three time points, with values of 43%, 56%, and 69%, compared to the Vehicle group's 25%, 36%, and 48%, respectively.*

FDA Label Image

Figure A (Figure A)

An instructional illustration showing a hand holding an ophthalmic suspension bottle, positioned as if about to administer eye drops. The hand supports the bottle with fingers and thumb around the label area and the bottle tip pointing upward.*

FDA Label Image

Figure B (Figure B)

An instructional illustration showing two hands holding a small bottle, with one hand grasping the body of the bottle and the other hand adjusting the cap. The bottle has a blank label area and is likely an ophthalmic suspension container similar to the Inveltys product by Alcon Laboratories.*

FDA Label Image

Figure C (Figure C)

A black-and-white line drawing illustration showing a hand holding an eye drop bottle upside down with a drop about to fall from the nozzle. The image depicts the administration of an ophthalmic suspension.*

FDA Label Image

Figure D (Figure D)

An instructional black-and-white illustration showing a person administering eye drops into the lower eyelid of the right eye. The person holds the bottle above the eye while gently pulling down the lower eyelid with the opposite hand. The image demonstrates the proper technique for applying ophthalmic suspension drops.*

FDA Label Image

Figure E (Figure E)

A black-and-white line drawing showing two hands holding an ophthalmic suspension bottle. One hand supports the bottle from underneath while the other grips and appears to twist the cap. The bottle label is blank without visible text or branding.*

FDA Label Image

Molecule (Mol)

Chemical structure of loteprednol etabonate, the active ingredient in Inveltys ophthalmic suspension 10 mg/mL by Alcon Laboratories, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.